SPPAM
LEGN icon

Summit Partners Public Asset Management’s Legend Biotech LEGN Stock Holding History

Summit Partners Public Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-130,000
Closed -$7.29M – 131
2024
Q1 		$7.29M Buy
+130,000
New +$7.84M 0.25% 86

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Summit Partners Public Asset Management's LEGN Position: Q2 2024 in Review

Summit Partners Public Asset Management sold out of Legend Biotech (LEGN) in Q2 2024, closing a stake of 235,493 shares — an estimated $13.2M sold.

Summit Partners Public Asset Management first reported a position in LEGN in Q3 2023 and held it in 3 quarters. The position peaked at $34.1M in Q4 2023. 181 funds tracked by Wall St. Rank hold LEGN as of Q2 2024.

  • Summit Partners Public Asset Management reported no remaining Legend Biotech position as of Q2 2024 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 235,493 Legend Biotech shares in Q2 2024, an estimated $13.2M.
  • Summit Partners Public Asset Management first reported a position in Legend Biotech in Q3 2023 and held it in 3 quarters.
  • Summit Partners Public Asset Management's Legend Biotech position peaked at $34.1M in Q4 2023.
  • 181 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2024.

Based on Summit Partners Public Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.